Our results could suggest that trastuzumab should be given postoperatively to patients with TP53(−)/ERBB2(+) ovarian carcinomas (in our study 18%) to enhance PS; as shown above, postoperative trastuzumab might be useless in patients with TP53(+)/ERBB2(+) carcinomas because in the TP53(+) group, ERBB2 expression does not diminish PS. This evidence concerns the gene TP53 and ovarian carcinoma.